Clinfidence
Clinfidence is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on disease activity in patients with Hidradenitis Suppurativa (HS)
Sponsor Citryll B.V.
- Start (EU)
- Latest update
- Estimated end
Phase 1/2, first-in-human, randomized, double-blind, reference-controlled study to evaluate the safety and immunogenicity of an extemporaneously mixed Combo Inactivated Influenza Vaccine (Green Cross [GC]-IIV; 15µg of each hemagglutinin [HA])/OVX836 (480µg), in comparison to GC-IIV (15µg of each HA) concomitantly administered with OVX836 (480µg), GC-IIV alone (15 µg each HA), OVX836 alone (480µg), and a licensed reference trivalent IIV (Vaxigrip®; 15µg of each HA), administered intramuscularly (IM) in healthy participants
Sponsor Osivax
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A prospective, randomized, evaluator- and subject blinded, multi-center investigation to assess efficacy and safety of three different dosages of the same injection pattern of LetibotulinumtoxinA in the treatment of moderate and severe horizontal forehead lines
Sponsor Croma-Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Adaptive Phase 3 Study to Evaluate the Efficacy and Safety of Sinecatechins (Defined Extract of Green Tea Leaves) Ointment in Adult Patients with Actinic Keratosis of the Scalp and the Face.
Sponsor Aresus Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years
Sponsor Osivax
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase IV multicenter immunogenicity and safety study of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults immunized with an H5N1/MF59 influenza vaccine, approximately 20 years before the trial, compared to H5 naive adult participants.
Sponsor University Of Antwerp
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 2a, single center, randomized, double-blind, study to evaluate the immunogenicity and safety of one single administration of OVX836 influenza vaccine at two dose levels (180µg or 480μg) given intramuscularly (IM), either as a booster or a primary vaccination in healthy adults previously administered with OVX836, Influvac Tetra® or placebo in the OVX836-002 (EudraCT number: 2019-002939-28) and OVX836-003 (EudraCT number: 2021-002535-39) studies
Sponsor OSIVAX Belgique
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihistamines
Sponsor Jasper Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A placebo controlled, randomized, double-blind, dose titration phase 2, safety and efficacy study of ORE-001 (oral lidocaine) in underweight elderly participants
Sponsor Orexa B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Clinfidence?
The 2026-10-09 snapshot links Clinfidence to 9 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Data management, Electronic data capture, Interactive response technology (IRT). These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Clinfidence?
The most frequently recorded therapeutic areas are Dermatology, Immunology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Clinfidence conducted?
The linked trials record locations in 9 countries, including Germany, Belgium, Netherlands, Austria, Spain. These are trial locations, not confirmed office locations or countries where Clinfidence delivered services.
What can this page tell me about Clinfidence's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Clinfidence. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Clinfidence B.V.